Journal of Clinical Oncology
Articles in this Issue
Delineating the role of the microbiome and tumor microenvironment interactions driving mucosal melanoma (MM) response and resistance to immune checkpoint inhibitor (ICI) treatment.
9561 Background: MM is a rare melanoma subtype with distinct biology and low response rates to ICIs. We seek to prospectively profile a cohort of MM patie...
Pathways to Advance Targeted and Helpful Serious Illness Conversations (PATH-SIC): A randomized clinical trial.
12013 Background: Serious illness conversations (SICs) can improve quality of life and decrease intensive care utilization at the end of life for patients...
A retrospective analysis of taxane-based chemotherapy in small bowel adenocarcinoma (SBA).
e16479 Background: Recent genomic data has demonstrated SBA to be a molecularly unique entity when compared to colon or gastric cancers. The ongoing SWOG...
HER2DX genomic test in HER2-positive breast cancer treated with 15 weeks of neoadjuvant paclitaxel, trastuzumab, and pertuzumab (THP): Final analysis from the BiOnHER clinical trial.
607 Background: HER2DX is a 27-gene genomic assay providing prognostic and predictive insights in early-stage HER2-positiv...
Phase 2 study of atezolizumab with carboplatin plus pemetrexed followed by maintenance atezolizumab with pemetrexed for elderly patients with advanced non-squamous non-small cell lung cancer: CJLSG1902.
8580 Background: Chemotherapy, including immune checkpoint inhibitors and platinum-containing agents, is a standard of care for patients with advanced non...
Second primary malignancy in patients with diffuse large B-cell lymphoma (DLBCL) receiving chimeric antigen receptor T-cell (CAR T) therapy and other systemic anti-cancer therapy: A real-world data analysis.
7080 Background: CAR T therapy is a recent class of treatment for DLBCL and has been linked to the development of second primary malignancy (SPM), specifi...
Targeting melanoma cells through G-quadruplex formation: Mechanism and enhanced efficacy of T-oligo in combination therapy.
e21605 Background: Melanoma is among the deadliest skin cancers, responsible for an estimated 7,990 annual deaths. Telomerase binds to the 3' overhang of...
Acute ischemic stroke in prostate cancer patients: Epidemiology, outcomes, and key insights from a national database.
e17002 Background: Cancer patients, including those with prostate cancer (PCA), face an elevated risk of acute ischemic stroke (AIS) due to mechanisms suc...
Hyperthermic intraperitoneal chemotherapy combined with cytoreductive surgery versus cytoreductive surgery alone for ovarian cancer: An updated meta-analysis.
5543 Background: Hyperthermic Intraperitoneal Chemotherapy (HIPEC) delivers high-dose chemotherapy directly to the abdomin...
Molecular characterization of <i> <i>CDK12</i> </i> mutation in Chinese CRPC and its impact on first-line endocrine therapy efficacy.
e17048 Background: Prostate cancer (PC) often develops resistance to androgen deprivation therapy (ADT) due to various secondary molecular mechanisms like...
Shifting cancer burden in developing countries: A comprehensive analysis of GLOBOCAN data, 2022.
e23307 Background: The global cancer landscape has undergone significant transformation over the past decade, with a notable shift in burden towards devel...
Clinical outcomes of metastatic urothelial carcinoma pts discontinuing enfortumab vedotin.
e16574 Background: Enfortumab vedotin (EV) monotherapy and its combination with pembrolizumab (EV/P) are established treatment options in metastatic uroth...
Postmarketing safety profile of chimeric antigen receptor (CAR) T cell therapies in diffuse large B-cell lymphoma (DLBCL): Analysis of real-world (RW) AE reporting from the FDA Adverse Event Reporting System (FAERS).
7028 Background: CAR T cell therapies have emerged as effective treatment options with deep and durable responses in patients (pt) with DLBCL. Although ef...
Use of CRISPR-KO screening to identify novel genes and pathways potentially contributing to cisplatin resistance in testicular germ cell tumors.
e17020 Background: Testicular germ cell tumors (TGCT) are the most common malignancy in young adult men, with a globally increasing incidence. While these...
Comparison of two electroacupuncture regimens on symptoms and brain structures in breast cancer survivors: A randomized, controlled trial.
12119 Background: Although electroacupuncture (EA) has shown usefulness in managing neuropsychiatric symptoms in cancer survivors, a specific acupoint reg...
The global, regional, and national burden of soft tissue sarcomas and other extraosseous sarcomas, 1990-2021: A systematic analysis for the Global Burden of Disease study 2021.
11548 Background: Soft tissue and other extraosseous sarcomas (STS) are a diverse group of cancers whose global burden have not been comprehensively repor...
Depression in patients with advanced prostate cancer in SWOG advanced cancer clinical trials.
12090 Background: Depression is common in patients with advanced cancer, but its prevalence has not been well documented. Moreover, depression is likely a...
Leveraging AI predictive models to develop thymic tumor–specific peptides mimicking COL17A1 alterations.
e20138 Background: We recently identified COL17A1 protein as a novel target in thymic epithelial tumors (TETs). Here, we designed tumor-specific peptides...
Validation and refinement of Society of Immunotherapy of Cancer (SITC) definitions for PD-(L)1 resistance: An analysis of more than 1,300 participants from SWOG.
2656 Background: New immuno-oncology (IO) agents are commonly used in patients who previously received PD-(L)1 inhibitors. In order to facilitate clinical...
ABLE-22: Safety and efficacy evaluation of nadofaragene firadenovec alone or in combination with chemotherapy or immunotherapy—A randomized, open-label, phase 2 study.
TPS4630 Background: Bacillus Calmette-Guérin (BCG) is the standard first-line therapy for patients with high-risk non–muscle-invasive bladder cancer (NMIB...
Comparing the safety and efficacy of small-versus medium-size particles in drug-eluting bead chemoembolization for hepatocellular carcinoma: A meta-analysis.
e16335 Background: The optimal microparticle size for drug-eluting beads transarterial chemoembolization (DEB-TACE) remains unknown. Studies have shown th...
Variation in communication of cancer risk in prostate cancer treatment consultations.
e23126 Background: Effective communication of cancer risk is essential for shared decision-making in prostate cancer treatment. We aimed to qualitatively...
Molecular changes in advanced clear cell renal cell carcinoma (ccRCC) pre- and post-immunotherapy.
e16533 Background: Whileimmunotherapy (IO) has improved outcomes for advanced ccRCC, biomarkers for IO response or resistance are lacking. Evaluating mole...
Prognostic scoring systems in first-line chemotherapy combined with immunotherapy: Unique predictive value of MDACC+NLR in ES-SCLC.
e20117 Background: This study aims to assess and validate the feasibility of seven prognostic scoring systems in predicting outcomes of first-line chemoth...
Progression patterns and clinical outcomes after anti-PD-1 therapy failure in patients with cutaneous squamous cell carcinoma.
e21521 Background: Cutaneous squamous cell carcinoma (CSCC) is the second most common cancer globally; however, advanced disease impacts a small subset of...